<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164975">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117297</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC-504</org_study_id>
    <secondary_id>L 10,394</secondary_id>
    <nct_id>NCT02117297</nct_id>
  </id_info>
  <brief_title>SCT Plus Immune Therapy in Average Risk AML/MDS</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation Following by Targeted Immune Therapy) (Gemtuzumab Ozogamicin) in Average Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome (AML/MDS)(IND 111024)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic stem cell transplantation followed by targeted immune therapy with Gemtuzumab
      Ozogamicin (Mylotarg) will be given to patients with average risk AML or MDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reduced intensity conditioning regimen of Busulfan and Fludarabine + Anti-Thymocyte Globulin
      (unrelated donors only)] and AlloSCT followed by Gemtuzumab Ozogamicin consolidation in
      patients with average risk AML/MDS meeting eligibility criteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>to evaluate incidence of graft failure</measure>
    <time_frame>Day +42</time_frame>
    <safety_issue>No</safety_issue>
    <description>If three or more of the first ten patients experience primary or secondary graft failure, we will discontinue the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to evaluate survival rates</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Event-free survival and overall survival after RI AlloSCT and targeted immunotherapy in patients with average risk AML/MDS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to determine toxicity</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>to monitor for serious adverse events related to protocol investigational therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minor histocompatibility antigen</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To measure the minor histocompatibility antigen expression on AML tissue, donor and recipient, and the development of MHA specific CTLs post AlloSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the degree of mixed/complete donor chimerism after RI AlloSCT in patients with average risk AML/MDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host disease</measure>
    <time_frame>1 Year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To estimate the risk of acute and chronic GVHD following RI AlloSCT and FK506/MMF GVHD prophylaxis in patients with average risk AML/MDS.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Gemtuzumab Ozogamicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consolidation therapy with GO will be administered between days 60 and 180 post transplantation when the ANC is &gt;1000/mm3 and platelet count is &gt;40,000/mm3 untransfused x 3 days after AlloSCT and again at minimum 8 weeks later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab Ozogamicin</intervention_name>
    <description>Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation.</description>
    <arm_group_label>Gemtuzumab Ozogamicin</arm_group_label>
    <other_name>Mylotarg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Disease Status:

          -  AML 1st CR with a matched family donor

          -  AML 1st CR with unrelated donor

          -  AML 2nd CR or CRP

          -  MDS and &lt; or = 5% bone marrow myeloblasts at diagnosis

        Disease Immunophenotype:

          -  Disease must express a minimum of &gt; or = 10% CD33 positivity for patients with AML

        Organ Function:

          -  Adequate renal function, adequate liver function, adequate cardiac function, adequate
             pulmonary function

        Exclusion Criteria:

          -  Patients with active CNS AML disease at time of preparative regimen

          -  Secondary MDS

          -  Poor cytogenetics

          -  Female patients who are pregnant

          -  Karnofsky &lt;70% or Lansky &lt;50% if 10 years or less

          -  Age &gt;30 years

          -  Seropositive for HIV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell S. Cairo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitchell S. Cairo, MD</last_name>
    <phone>(914) 594-2150</phone>
    <email>mitchell_cairo@nymc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Morris, RN</last_name>
    <phone>(714) 964-5359</phone>
    <email>erin_morris@nymc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Vallhala</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell S Cairo, MD</last_name>
      <phone>914-594-2150</phone>
      <email>mitchell_cairo@nymc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erin Morris, RN</last_name>
      <phone>714-964-5359</phone>
      <email>erin_morris@nymc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mitchell S. Cairo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Mitchell Cairo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
